Drug Profile
Research programme: adult stem cell-based retinal therapy - Lisata Therapeutics/Schepens Eye Research Institute
Latest Information Update: 19 Sep 2022
Price :
$50
*
At a glance
- Originator NeoStem; Schepens Eye Research Institute
- Developer Lisata Therapeutics; Schepens Eye Research Institute
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration; Glaucoma; Retinal disorders
Most Recent Events
- 14 Sep 2022 Cend Therapeutics has merged with Caladrius Biosciences to form Lisata Therapeutics
- 28 Jul 2018 No recent reports of development identified for research development in Retinal-disorders in USA (Ophthalmic, Implant)
- 16 Jul 2016 No recent reports of development identified for research development in Age-related-macular-degeneration in USA (Ophthalmic, Implant)